IQVIA Holdings (IQV) has been in focus after selecting multiple Veeva clinical applications as enterprise standards across its studies, a move that sharpens attention on how the stock reflects its clinical tech partnerships.
IQVIA Holdings has paired these product and partnership announcements with strong market interest, with the share price climbing 26.1% over the past 90 days and the 1-year total shareholder return reaching 27.3%, even though very recent daily moves have been quieter.
Spot 33 healthcare AI stocks that, like IQVIA Holdings, are tying advanced data and clinical technology to real-world adoption in healthcare.After a 26.1% move in 90 days and a 1-year total return of 27.3%, IQVIA Holdings now presents a simple question to investors: pay today’s price, or wait and hope the valuation offers another opportunity.
Most Popular Narrative: 8% Undervalued
IQVIA Holdings last closed at $260.68, while the most followed narrative pegs fair value at about $283.56. The debate revolves around whether current momentum and AI adoption fully capture that long term story.
Faster growth in Commercial Solutions, including double digit reported growth in early 2026 and the strongest analytics and consulting growth in three years, along with record pipelines and better win rates, gives IQVIA Holdings more opportunity to grow higher margin services that support earnings and cash flow.
See why 19 investors see IQVIA Holdings as 8% undervalued.
Result: Fair Value of $283.56 (UNDERVALUED)
Still, IQVIA Holdings carries real pressure points, including CRO pricing strain and a sizeable debt load that could squeeze margins and limit future financial flexibility.
Find out about the key risks to this IQVIA Holdings narrative.
Next Steps
With IQVIA Holdings pulling in both optimism and concern, you should move quickly, review the underlying data, and weigh the 3 key rewards and 2 important warning signs.
Looking for more IQVIA-like investment ideas?
If IQVIA Holdings has your attention, do not stop here. Broaden your watchlist with other opportunities filtered by quality, value, and resilience using the Simply Wall Street Screener.
- Target undervalued quality by reviewing companies that screen as 32 high quality undervalued stocks and could offer more attractive entry points than IQVIA Holdings.
- Strengthen portfolio resilience by focusing on businesses in the list of solid balance sheet and fundamentals (25 results) that pair healthier finances with more flexibility through different market conditions.
- Get ahead of the crowd by hunting for potential future leaders in the 20 high quality undiscovered gems before broader attention pushes prices higher.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com